International Stem Cell (ISCO) Gross Margin (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Gross Margin of 50.53% for Q4 2025, down 899.0% year-over-year from 6.32% in Q4 2024, and down 9.38% quarter-over-quarter from 55.76% in Q3 2025.
International Stem Cell (ISCO) Gross Margin (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Gross Margin for 16 consecutive years, with 50.53% the latest figure, recorded in Q4 2025.
- In Q4 2025, Gross Margin fell 899.0% year-over-year to 50.53%; the TTM figure through Dec 2025 stood at 55.68% (down 289.0% YoY), while the FY2025 annual figure was 55.68%, down 289.0% from the prior year.
- Gross Margin declined to 50.53% in Q4 2025 per ISCO's latest filing, from 55.76% in the prior quarter.
- Across five years, Gross Margin topped out at 64.58% in Q2 2022 and bottomed at 50.53% in Q4 2025.
- Historically, Gross Margin has averaged 58.53% across 5 years, with a median of 59.5% in 2024.
- Annual changes were most pronounced in 2022 — Gross Margin surged 659 bps — and 2025, when it plunged 899 bps.
- International Stem Cell's Gross Margin stood at 60.12% in 2021, then decreased by 11 bps to 53.25% in 2022, then climbed by 2 bps to 54.31% in 2023, then increased by 10 bps to 59.53% in 2024, then dropped by 15 bps to 50.53% in 2025.
- Business Quant data shows ISCO's Gross Margin at 50.53% in Q4 2025, 55.76% in Q3 2025, and 62.12% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 76.90% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 84.20% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 63.27% |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 54.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.50% |
| Dec 31, 2025 | 50.53% |
| Sep 30, 2025 | 55.76% |
| Jun 30, 2025 | 62.12% |
| Mar 31, 2025 | 53.41% |
| Dec 31, 2024 | 59.53% |
| Sep 30, 2024 | 55.30% |
| Jun 30, 2024 | 60.83% |
| Mar 31, 2024 | 58.34% |
| Dec 31, 2023 | 54.31% |
| Sep 30, 2023 | 60.42% |
| Jun 30, 2023 | 61.27% |
| Mar 31, 2023 | 60.50% |
| Dec 31, 2022 | 53.25% |
| Sep 30, 2022 | 59.48% |
| Jun 30, 2022 | 64.58% |
| Mar 31, 2022 | 64.11% |
| Dec 31, 2021 | 60.12% |
| Sep 30, 2021 | 55.81% |
| Jun 30, 2021 | 57.99% |